The p.A854D variant (also known as c.2561C>A), located in coding exon 15 of the PMS2 gene, results from a C to A substitution at nucleotide position 2561. The alanine at codon 854 is replaced by aspartic acid, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
ClinVar Genomic variation as it relates to human health
NM_000535.7(PMS2):c.2561C>A (p.Ala854Asp)
Germline
Classification
Help
The aggregate germline classification for this variant, typically for a monogenic or Mendelian disorder as in the ACMG/AMP guidelines, or for response to a drug. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the aggregate classification.
(1)
Help
Stars represent the aggregate review status, or the level of review supporting the aggregate germline classification for this VCV record. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. The number of submissions which contribute to this review status is shown in parentheses.
Uncertain significance
1
criteria provided, single submitter
Somatic
No data submitted for somatic clinical impact
Somatic
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NM_000535.7(PMS2):c.2561C>A (p.Ala854Asp)
Variation ID: 1793119 Accession: VCV001793119.2
- Type and length
-
single nucleotide variant, 1 bp
- Location
-
Cytogenetic: 7p22.1 7: 5973427 (GRCh38) [ NCBI UCSC ] 7: 6013058 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline Nov 29, 2022 May 1, 2024 Sep 8, 2022 - HGVS
-
... more HGVS ... less HGVSNucleotide Protein Molecular
consequenceNM_000535.7:c.2561C>A MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NP_000526.2:p.Ala854Asp missense NM_001018040.1:c.2156C>A NP_001018050.1:p.Ala719Asp missense NM_001322003.2:c.2156C>A NP_001308932.1:p.Ala719Asp missense NM_001322004.2:c.2156C>A NP_001308933.1:p.Ala719Asp missense NM_001322005.2:c.2156C>A NP_001308934.1:p.Ala719Asp missense NM_001322006.2:c.2405C>A NP_001308935.1:p.Ala802Asp missense NM_001322007.2:c.2243C>A NP_001308936.1:p.Ala748Asp missense NM_001322008.2:c.2243C>A NP_001308937.1:p.Ala748Asp missense NM_001322009.2:c.2189C>A NP_001308938.1:p.Ala730Asp missense NM_001322010.2:c.2000C>A NP_001308939.1:p.Ala667Asp missense NM_001322011.2:c.1628C>A NP_001308940.1:p.Ala543Asp missense NM_001322012.2:c.1628C>A NP_001308941.1:p.Ala543Asp missense NM_001322013.2:c.1988C>A NP_001308942.1:p.Ala663Asp missense NM_001322014.2:c.2594C>A NP_001308943.1:p.Ala865Asp missense NM_001322015.2:c.2252C>A NP_001308944.1:p.Ala751Asp missense NM_001406866.1:c.2747C>A NP_001393795.1:p.Ala916Asp missense NM_001406868.1:c.2585C>A NP_001393797.1:p.Ala862Asp missense NM_001406869.1:c.2453C>A NP_001393798.1:p.Ala818Asp missense NM_001406870.1:c.2438C>A NP_001393799.1:p.Ala813Asp missense NM_001406871.1:c.2417C>A NP_001393800.1:p.Ala806Asp missense NM_001406872.1:c.2393C>A NP_001393801.1:p.Ala798Asp missense NM_001406873.1:c.2363C>A NP_001393802.1:p.Ala788Asp missense NM_001406874.1:c.2393C>A NP_001393803.1:p.Ala798Asp missense NM_001406875.1:c.2285C>A NP_001393804.1:p.Ala762Asp missense NM_001406876.1:c.2276C>A NP_001393805.1:p.Ala759Asp missense NM_001406877.1:c.2252C>A NP_001393806.1:p.Ala751Asp missense NM_001406878.1:c.2252C>A NP_001393807.1:p.Ala751Asp missense NM_001406879.1:c.2252C>A NP_001393808.1:p.Ala751Asp missense NM_001406880.1:c.2252C>A NP_001393809.1:p.Ala751Asp missense NM_001406881.1:c.2252C>A NP_001393810.1:p.Ala751Asp missense NM_001406882.1:c.2252C>A NP_001393811.1:p.Ala751Asp missense NM_001406883.1:c.2243C>A NP_001393812.1:p.Ala748Asp missense NM_001406884.1:c.2237C>A NP_001393813.1:p.Ala746Asp missense NM_001406885.1:c.2225C>A NP_001393814.1:p.Ala742Asp missense NM_001406886.1:c.2195C>A NP_001393815.1:p.Ala732Asp missense NM_001406887.1:c.2189C>A NP_001393816.1:p.Ala730Asp missense NM_001406888.1:c.2189C>A NP_001393817.1:p.Ala730Asp missense NM_001406889.1:c.2156C>A NP_001393818.1:p.Ala719Asp missense NM_001406890.1:c.2156C>A NP_001393819.1:p.Ala719Asp missense NM_001406891.1:c.2156C>A NP_001393820.1:p.Ala719Asp missense NM_001406892.1:c.2156C>A NP_001393821.1:p.Ala719Asp missense NM_001406893.1:c.2156C>A NP_001393822.1:p.Ala719Asp missense NM_001406894.1:c.2156C>A NP_001393823.1:p.Ala719Asp missense NM_001406895.1:c.2156C>A NP_001393824.1:p.Ala719Asp missense NM_001406896.1:c.2156C>A NP_001393825.1:p.Ala719Asp missense NM_001406897.1:c.2156C>A NP_001393826.1:p.Ala719Asp missense NM_001406898.1:c.2156C>A NP_001393827.1:p.Ala719Asp missense NM_001406899.1:c.2156C>A NP_001393828.1:p.Ala719Asp missense NM_001406900.1:c.2096C>A NP_001393829.1:p.Ala699Asp missense NM_001406901.1:c.2087C>A NP_001393830.1:p.Ala696Asp missense NM_001406902.1:c.2087C>A NP_001393831.1:p.Ala696Asp missense NM_001406903.1:c.2075C>A NP_001393832.1:p.Ala692Asp missense NM_001406904.1:c.2048C>A NP_001393833.1:p.Ala683Asp missense NM_001406905.1:c.2048C>A NP_001393834.1:p.Ala683Asp missense NM_001406906.1:c.2000C>A NP_001393835.1:p.Ala667Asp missense NM_001406907.1:c.2000C>A NP_001393836.1:p.Ala667Asp missense NM_001406908.1:c.1988C>A NP_001393837.1:p.Ala663Asp missense NM_001406909.1:c.1988C>A NP_001393838.1:p.Ala663Asp missense NM_001406910.1:c.1844C>A NP_001393839.1:p.Ala615Asp missense NM_001406911.1:c.1790C>A NP_001393840.1:p.Ala597Asp missense NM_001406912.1:c.1358C>A NP_001393841.1:p.Ala453Asp missense NR_003085.2:n.2643C>A NR_136154.1:n.2605C>A non-coding transcript variant NC_000007.14:g.5973427G>T NC_000007.13:g.6013058G>T NG_008466.1:g.40680C>A LRG_161:g.40680C>A LRG_161t1:c.2561C>A LRG_161p1:p.Ala854Asp - Protein change
- A543D, A597D, A692D, A762D, A788D, A854D, A865D, A916D, A453D, A615D, A732D, A742D, A818D, A667D, A683D, A699D, A730D, A748D, A798D, A802D, A663D, A696D, A719D, A746D, A751D, A759D, A806D, A813D, A862D
- Other names
- -
- Canonical SPDI
- NC_000007.14:5973426:G:T
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
- -
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
- -
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
- -
- Links
Genes
| Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
|---|---|---|---|---|---|---|
| HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
| PMS2 | Sufficient evidence for dosage pathogenicity | No evidence available |
GRCh38 GRCh37 |
5241 | 5343 | |
Conditions - Germline
| Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
|---|---|---|---|---|
| Uncertain significance (1) |
criteria provided, single submitter
|
Sep 8, 2022 | RCV002452735.2 |
Submissions - Germline
| Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
|---|---|---|---|---|---|
|
Uncertain significance
(Sep 08, 2022)
|
criteria provided, single submitter
Method: clinical testing
|
Hereditary cancer-predisposing syndrome
Affected status: unknown
Allele origin:
germline
|
Ambry Genetics
Accession: SCV002740213.2
First in ClinVar: Nov 29, 2022 Last updated: May 01, 2024 |
Comment:
The p.A854D variant (also known as c.2561C>A), located in coding exon 15 of the PMS2 gene, results from a C to A substitution at nucleotide … (more)
The p.A854D variant (also known as c.2561C>A), located in coding exon 15 of the PMS2 gene, results from a C to A substitution at nucleotide position 2561. The alanine at codon 854 is replaced by aspartic acid, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. (less)
|
Comment:
Germline Functional Evidence
| There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Comment:
The p.A854D variant (also known as c.2561C>A), located in coding exon 15 of the PMS2 gene, results from a C to A substitution at nucleotide position 2561. The alanine at codon 854 is replaced by aspartic acid, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Citations for germline classification of this variant
Help| There are no citations for germline classification of this variant in ClinVar. If you know of citations for this variation, please consider submitting that information to ClinVar. |
Text-mined citations for this variant ...
HelpRecord last updated May 01, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.